Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XNZXI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Labetuzumab-PE40 conjugate
|
|||||
| Synonyms |
AntiCEA monoclonal antibody MN14PE40 conjugate; hMN14 (sFv)PE40 immunotoxin
Click to Show/Hide
|
|||||
| Organization |
Immunomedics, Inc.; Gilead Sciences, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Clinical candidate
|
|||||
| Antibody Name |
Labetuzumab
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
|
Antigen Info | ||||
| Payload Name |
Pseudomonas exotoxin PE40
|
Payload Info | ||||
| Therapeutic Target |
Eukaryotic elongation factor 2 (EEF2)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.